Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Development of Novel Immune Checkpoint Blockade Therapies in Mouse Models of Invasive Lobular Breast Carcinoma

FY 2022-23

Summary
Invasive Lobular Carcinoma (ILC) of the breast is the most common Breast Cancer subtype, which accounts for ~10% of BC cases. By ~10 years post diagnosis, ILC patients show worse survival in comparison to patients with most other subtypes, and death from ILC is associated with therapy resistant and metastatic disease. The incurable nature of recurrent and metastatic ILC highlights the need to develop therapies for recurrent disease. Immune checkpoint blockade is a form of cancer therapy based on activation of a potent but dormant anti-tumor response. However, typical models for ILC are based on injection of human tumor cells into immunocompromised mice which are not well suited for use in the development of immune checkpoint blockade-based therapy. The Egan lab has developed mouse models for ILC at presentation and recurrence in immune competent mice. The model for ILC at presentation displays a characteristic immune-excluding phenotype, whereby immune cells are attracted to the tumor but are unable to get through a stiff extracellular matrix barrier to attack it. On recurrence, fewer immune cells are attracted to the tumor. The objectives of my project are to; i) develop a therapeutic strategy to target ILC at presentation based on alleviating immune exclusion by shutting down TGFb-induced collagen matrix deposition in these tumors, and ii) develop a therapeutic strategy to target metastatic ILC based on Giredestrant-mediated inhibition of the recurrence-associated ESR1 mutant protein combined with immune checkpoint blockade therapy. Importantly, these new models for ILC developed in the Egan lab provide a powerful and novel way to develop immune based therapeutics for the treatment of a common and devastating form of BC.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486202
Name
Pfeil Jennifer Q
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of Novel Immune Checkpoint Blockade Therapies in Mouse Models of Invasive Lobular Breast Carcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Pd-L1 Therapy; Breast Cancer; Combination Therapy; Immune Checkpoint Therapy; Immune-Evasion; Invasive Lobular Carcinoma; Metastatic Disease; Mouse Model; Mutant Esr1; Resistant Disease
Abstract
Invasive Lobular Carcinoma (ILC) of the breast is the most common Breast Cancer subtype, which accounts for ~10% of BC cases. By ~10 years post diagnosis, ILC patients show worse survival in comparison to patients with most other subtypes, and death from ILC is associated with therapy resistant and metastatic disease. The incurable nature of recurrent and metastatic ILC highlights the need to develop therapies for recurrent disease. Immune checkpoint blockade is a form of cancer therapy based on activation of a potent but dormant anti-tumor response. However, typical models for ILC are based on injection of human tumor cells into immunocompromised mice which are not well suited for use in the development of immune checkpoint blockade-based therapy. The Egan lab has developed mouse models for ILC at presentation and recurrence in immune competent mice. The model for ILC at presentation displays a characteristic immune-excluding phenotype, whereby immune cells are attracted to the tumor but are unable to get through a stiff extracellular matrix barrier to attack it. On recurrence, fewer immune cells are attracted to the tumor. The objectives of my project are to; i) develop a therapeutic strategy to target ILC at presentation based on alleviating immune exclusion by shutting down TGFb-induced collagen matrix deposition in these tumors, and ii) develop a therapeutic strategy to target metastatic ILC based on Giredestrant-mediated inhibition of the recurrence-associated ESR1 mutant protein combined with immune checkpoint blockade therapy. Importantly, these new models for ILC developed in the Egan lab provide a powerful and novel way to develop immune based therapeutics for the treatment of a common and devastating form of BC.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pfeil, Jennifer Q
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~